Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800–322–4349. The November 2014 monograph topics are suvorexant, idelalisib, belinostat for injection, C1 esterase inhibitor, and ledipasvir. The DUE/MUE is on suvorexant.
ImW.B.ChoiS.H.ParkJ.Y.ChoiS.H.FinnJ.YoonS.H.Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem.2011; 46(4): 1027–1039.
3.
LivermoreD.M.MushtaqS.WarnerM.WoodfordN.Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother.2009; 63(4): 713–715.
4.
YumJ.H.ChoiS.H.YongD.Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. Antimicrob Agents Chemother.2010; 54(12): 5381–5386.
5.
GoldenA.BaxterM.NicholK.A.AdamH.J.HobanD.J.ZhanelG.G.In vitro activity of tedizolid against Canadian clinical gram-positive pathogens, including hVISA and the CDC NARSA strains [abstract]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10–13, 2013; Denver, CO. Abstract E-143.
6.
BrownS.D.TraczewskiM.M.Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother.2010; 54(5): 2063–2069.
7.
SchaadtR.SweeneyD.ShinabargerD.ZurenkoG.In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother.2009; 53(8): 3236–3239.
8.
BetriuC.MoralesG.Rodríguez-AvialI.Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob Agents Chemother.2010; 54(5): 2212–2215.
9.
ShawK.J.PoppeS.SchaadtR.In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother.2008; 52(12): 4442–4427.
10.
Rodríguez-AvialI.CulebrasE.BetriuC.MoralesG.PenaI.PicazoJ.J.In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother.2012; 67(1): 167–169.
11.
JonesR.N.MoetG.J.SaderH.S.MendesR.E.CastanheiraM.TR-700 in vitro activity against and resistance mutation frequencies among gram-positive pathogens. J Antimicrob Chemother.2009; 63(4): 716–720.
12.
ProkocimerP.BienP.DeandaC.PillarC.M.BartizalK.In vitro activity and microbiological efficacy of tedizolid (TR-700) against gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother.2012; 56(9): 4608–4613.
13.
LockeJ.B.ZuillD.E.ScharnC.R.Characterization of cfr-positive linezolid-resistant USA300 Staphylococcus aureus isolates collected from a New York City Medical Center [abstract]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10–13, 2013; Denver, CO. Abstract C1–517.
14.
ThomsonK.S.GoeringR.V.Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origin. Antimicrob Agents Chemother.2013; 57(6): 2892–2895.
15.
DeaneJ.SimenauerA.BartizalK.In vitro activity profile of tedizolid (TZD) and correlations with linezolid (LZD) activity against recent Staphylococcal isolates. [abstract]. Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9–12, 2012; San Francisco, CA.
16.
BienP.ProkocimerP.MunozK.A.BethuneC.Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects [abstract]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2010; Boston, MA.
17.
HousmanS.T.PopeJ.S.RussomannoJ.Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother.2012; 56(5): 2627–2634.
18.
OngV.FlanaganS.FangE.Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos.2014; 42(8): 1275–1284.
19.
MondickJ.BienP.DeAndaC.GastonguayP.ProkocimerP.Population pharmacokinetic modeling of TR-700 in patients with complicated skin and skin structure infections [abstract]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2010; Boston, MA. Abstract A1–014.
20.
FlanaganS.PassarellJ.LuQ.Fiedler-KellyJ.ProkocimerP.Tedizolid population pharmacokinetics, exposure-response, and target attainment. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10–13, 2013; Denver, CO. Abstract A-017c.
21.
BienP.MuñozK.A.BohnJ.WrightR.BethuneC.ProkocimerP.Human pharmacokinetics of TR-700 after ascending single oral doses of the prodrug TR-701, a novel oxazolidinone antibiotic [abstract]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25–28, 2008; Washington, DC.
22.
FlanaganS.MorrisD.BoyeaT.A phase 1 study of intravenously administered tedizolid phosphate in subjects with advanced renal impairment [abstract]. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9–12, 2012; San Francisco, CA. Abstract A-1294.
StevensD.L.BisnoA.L.ChambersH.F.; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis.2005; 41(10): 1373–1406.
25.
MoranG.J.FangE.CoreyG.R.DasA.F.De AndaC.ProkocimerP.Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis.2014; 14(8) 696–705.
26.
De AndaC.FangE.DasA.ProkocimerP.Integrated results from phase 3 studies comparing tedizolid 6 days vs linezolid 10 days in patients with ABSSSI [abstract]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10–13, 2013; Denver, CO.
27.
ProkocimerP.De AndaC.FangE.MehraP.DasA.Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial. JAMA.2013; 309(6): 559–569.
28.
ProkocimerP.BienP.SurberJ.Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother.2011; 55(2): 583–592.
29.
DasD.TulkensP.M.MehraP.FangE.ProkocimerP.Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: Safety summary. Clin Infect Dis.2014; 58(suppl 1): S51–S57.
30.
FlanaganS.BartizalK.MinassianS.L.FangeE.ProkocimerP.In vitro, in vivo, and clinical studies to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother.2013; 57(7): 3060–3066.
31.
FlanaganS.MinassianS.FangE.Lack of MAO inhibition by tedizolid phosphate in clinical and nonclinical studies [abstract]. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9–12, 2012; San Francisco, CA. Abstract 1295a.
